Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 2/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706685 | 0.74 | MAPT (0.45) | — | |
| SCHEMBL4451027 | 0.72 | KDM4E (0.52) | — | |
| SCHEMBL7376072 | 0.72 | ACLY (0.35) | — | |
| SCHEMBL25439911 | 0.70 | ENPP2 (0.44) | — | |
| SCHEMBL28626852 | 0.69 | ESR1 (0.50) | MMP3 | |
| SCHEMBL13666303 | 0.69 | NTRK1 (0.41) | NTRK1 | |
| SCHEMBL28716802 | 0.69 | NOTUM (0.32) | — | |
| SCHEMBL24921498 | 0.69 | HTT (0.57) | — | |
| SCHEMBL1609941 | 0.69 | ALDH1A1 (0.55) | — | |
| SCHEMBL19567894 | 0.69 | TSHR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569317-B2 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-7696216-B2 | Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20100063075-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | ALTMANN EVA | 2010-03-11 | — | — | US | disclosed |
| EP-1585521-B1 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1844780-A2 | Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone | Novartis Pharma AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060079685-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079685-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | PTH1R, PTMS, CYP24A1 | NTRK1 573/4885MMP8 1746/4885MMP3 239/4885 |
| US-20100063075-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | PTH1R, PTMS, CYP24A1 | NTRK1 611/4885MMP8 1760/4885MMP3 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.